Most Read Articles
Pearl Toh, 6 days ago
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
5 days ago
Transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) have comparable safety in low-risk surgical patients, reports a new meta-analysis.
2 days ago
Eating alone may help in weight management as findings of a recent study suggest that eating with friends lead to higher food intake.
Elvira Manzano, 09 Oct 2019
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.

Podcast: Professor Oliver Distler talks about the utility of nintedanib in ILD in the SENSCIS trial

07 Jun 2019
Podcast: Professor Oliver Distler talks about the utility of nintedanib in ILD in the SENSCIS trial
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
5 days ago
Transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) have comparable safety in low-risk surgical patients, reports a new meta-analysis.
2 days ago
Eating alone may help in weight management as findings of a recent study suggest that eating with friends lead to higher food intake.
Elvira Manzano, 09 Oct 2019
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.